Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Summary as of Jun 27, 2018

June 27, 2018 - By Ira Colvard

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
Big Money Sentiment decreased to 2.44 in Q1 2018. It has change of 0.56, from 2017Q4’s 3. The ratio dropped due to Dicerna Pharmaceuticals, Inc. positioning: 3 sold and 13 reduced. 24 funds amassed stakes and 15 increased stakes. Investors holded 29.10 million in 2017Q4 but now own 30.68 million shares or 5.45% more.
Spark Investment Mgmt Limited Liability reported 145,000 shs. Vanguard holds 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 1.23M shs. Birchview Capital Limited Partnership invested in 45,000 shs. 23,566 are held by Acadian Asset Mngmt Ltd Liability Co. Price T Rowe Assoc Incorporated Md has 83,594 shs. Ra Capital Mngmt Limited Co has 3.93M shs. Ecor1 Limited Co invested in 4.76 million shs or 4.57% of the stock. Cubist Systematic Strategies holds 0.01% or 10,665 shs. Northern Corporation reported 59,384 shs. New York-based Laurion Capital Management Ltd Partnership has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Tower Cap Ltd Limited Liability Company (Trc) holds 0% or 1,536 shs in its capital. 82,957 were accumulated by Element Cap Mgmt Lc. Comml Bank Of America De holds 0% or 8,491 shs. Ghost Tree Ltd Llc has invested 1.84% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 41,432 are held by Bancshares Of Ny Mellon.

Dicerna Pharmaceuticals, Inc. had 4 selling transactions and 0 insider purchases since March 19, 2018. This’s net activity of $425,035. $145,035 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shs were sold by Brown Bob D.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

Total analysts of 8 have positions in Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 4 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 50%. The firm has $17 highest while $10 is the lowest target price. The average target $11.83 is -3.74% below the last ($12.29) price. Since January 16, 2018 according to StockzIntelligence Inc Dicerna Pharmaceuticals has 8 analyst reports. On Friday, March 9 the company was initiated by Chardan Capital Markets. On Friday, March 9 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus. On Monday, February 5 SunTrust initiated the shares of DRNA in report with “Buy” rating. On Wednesday, April 11 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given by Cowen & Co. On Friday, March 23 H.C. Wainwright downgraded Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to “Neutral” rating. On Tuesday, March 27 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Hold” rating by FBR Capital. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

11/04/2018 Broker: Cowen & Co Rating: Buy Initiate
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $10 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $10.0000 Initiate
23/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $7 Downgrade
09/03/2018 Broker: Chardan Capital Markets Rating: Hold Initiate
09/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $10 New Target: $17 Maintain
05/02/2018 Broker: SunTrust Rating: Buy New Target: $13.0 Initiate
16/01/2018 Broker: Evercore Rating: Outperform New Target: $14 Initiates Coverage On

DRNA is touching $12.29 during the last trading session, after decreased 7.18%.Dicerna Pharmaceuticals, Inc. has volume of 467,650 shares. Since June 27, 2017 DRNA has risen 317.27% and is uptrending. DRNA outperformed by 304.70% the S&P500.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is worth $649.18 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Last it reported negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.